ICON has acquired Veeda Laboratories, a wholly-owned subsidiary of Veeda Clinical Research Group.
The acquisition adds to ICON Development Solutions’ existing bioanalytical and immunoassay capabilities, which are delivered through its laboratory in Manchester, UK, and Prevalere Life Sciences, a US-based bioanalytical and immunoassay laboratory.
Thomas Frey, President of Development Solutions at ICON, said: “Biomarkers of disease are assuming an ever increasing role in the discovery and development of drugs. In Veeda Laboratories, we have acquired a company that has a very strong reputation for biomarker development and has well-established relationships with top-tier pharmaceutical and biotechnology companies. Veeda’s team of scientists will also greatly enhance ICON’s existing team of biomarker experts.”
John Allinson, Head of Veeda Laboratories, said: “We are excited to be joining ICON. This deal will enable us to enhance and expand our biomarker, pharmacokinetic and immunogenicity services and to offer our clients a broader suite of drug development services. We look forward to working closely with ICON’s global network of laboratories to develop innovative biomarker solutions that improve clients’ drug development and therapeutic decision making.”